drugset
drugset / Trial / NCT03916250

Evaluation of Skin Irritation Potential With PF-06700841 Cream Formulation Using Negative Control in Adult Japanese Healthy Participants

NCT03916250 ↗

Phase 1 Completed 20 enrolled Pfizer
RandomizedParallel-groupDouble-blindTreatment

Summary

This is a Phase 1, single center, randomized, vehicle and white petrolatum controlled, evaluator blinded study to assess the skin irritation potential with a range of concentrations of PF-06700841 cream including vehicle and empty patch with white petrolatum under occlusive conditions in adult Japanese healthy participants.

Timeline

Start
2019-03-23
Primary completion
2019-04-15
Completion
2019-05-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Brepocitinib Small molecule 0 % Topical
Subject Brepocitinib Small molecule 0.1 % Topical
Subject Brepocitinib Small molecule 0.3 % Topical
Subject Brepocitinib Small molecule 1 % Topical
Subject Brepocitinib Small molecule 3 % Topical

Indications

No indication recorded.